Table 3.

Callers’ reasons for calling neurologists’ offices: comparison with fingolimod

Call reason	Fingolimod	IM IFN β-1a		IFN β-1b (Betaseron® /Extavia®)		Glatiramer acetate		SC IFN β-1a
	N=82	N=99	P-value			N=100	P-value	N=96	P-value
				N=84	P-value
Obtain medical information	15 (18.3%)	10 (10.1%)	<0.0001	7 (8.3%)	<0.0001	16 (16.0%)	0.0002	7 (7.3%)	<0.0001
Side effects	22 (26.8%)	81 (81.8%)		70 (83.3%)		59 (59.0%)		80 (83.3%)
Insurance coverage	34 (41.5%)	5 (5.1%)		5 (6.0%)		16 (16.0%)		4 (4.2%)
Financial assistance	5 (6.1%)	0 (0.0%)		0 (0.0%)		5 (5.0%)		2 (2.1%)
Other	6 (7.3%)	3 (3.0%)		2 (2.4%)		4 (4.0%)		3 (3.1%)

Notes: Betaseron^®; Bayer AG, Leverkusen, Germany. Extavia^®; Novartis AG, Basel, Switzerland.

Abbreviations: N, number; IM, intramuscular; IFN, interferon; SC, subcutaneous.